Iurlo, Alessandra; Cattaneo, Daniele; Malato, Alessandra; Accurso, Vincenzo; Annunziata, Mario; Gozzini, Antonella; Scortechini, Anna Rita; Bucelli, Cristina; Scalzulli, Emilia; Attolico, Imma; Maggi, Alessandro; Martino, Bruno; Caocci, Giovanni; Abruzzese, Elisabetta; Pregno, Patrizia; Luciano, Luigiana; Breccia, Massimo published an article in 2020, the title of the article was Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs.SDS of cas: 380843-75-4 And the article contains the following content:
Ponatinib is a potent, orally available, third-generation tyrosine kinase inhibitor (TKI) with proven efficacy in both mutated and unmutated BCR-ABL1-pos. chronic myeloid leukemia (CML) patients including the gatekeeper T315I mutation. While its efficacy has been firstly confirmed in the pivotal phase II PACE trial, nevertheless, when used at the recommended starting dose of 45 mg/d ponatinib raised some concerns due to an increased risk of cardiovascular (CV) adverse events (AEs). In fact, when assessed in a hind limb ischemia model, owing to its multikinase inhibitory properties ponatinib may cause endothelial dysfunction. Ponatinib may affect targets such as VEGFR and promote the expression of proatherogenic surface adhesion receptors. Since these effects were found to be dose-related, suggesting a direct relationship between CV AEs and ponatinib dosage, a reduction of the daily dose has been advised for patients who already achieved at least a major cytogenetic response (MCyR). The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).SDS of cas: 380843-75-4
The Article related to ponatinib chronic myeloid leukemia patient tyrosine kinase inhibitor, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.SDS of cas: 380843-75-4
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics